Ablynx Says No Partner Required To Get Rare Disease Drug To Market

Ablynx says it plans to retain 100% ownership of its thrombotic thrombocytopenic purpura (TTP) therapy, caplacizumab, rather than seek commercialization deals in Europe and the US following Phase III studies.